CD8A and cancer: Cancer treatments with immune checkpoint inhibitors targeting CTLA-4 or the PD-1/PD-L1 axis can prevent dysfunction of tumor-directed CD8 T-cell responses and have shown durable responses in humans with advanced cancers49.